Webinar Technology

Deciphering fibrosis: Exploring the biological drivers of fibrotic disease in the liver and heart

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Deciphering fibrosis: Exploring the biological drivers of fibrotic disease in the liver and heart

20 February 2019

12:00 p.m. ET

Register to watch recording

Speakers

Fibrotic diseases of the heart and liver impact a significant portion of the global population and are a growing public health concern. Fibrosis occurs when fibroblasts deposit excess extracellular material within the tissue in response to certain stimuli or injury. Myocardial fibrosis is associated with nearly all forms of heart disease. The pathological changes that can result from fibrosis include cardiomyocyte hypertrophy, chamber dilation, heart valve stiffening, and others, all of which contribute to heart failure. Nonalcoholic steatohepatitis (NASH) is a fatty liver disease characterized by hepatocyte inflammation that contributes to fibrosis, cirrhosis, and liver failure. NASH is closely linked to obesity and diabetes; changes in diet have thus contributed to its expansion and impact across the globe. Understanding the underlying biology of fibrosis is critical for the diagnosis, treatment, and management of cardiac fibrosis, NASH, and other fibrotic diseases.

During the webinar, viewers will:

  • Hear about how fibrosis can contribute to diseases of the heart and liver
  • Learn more about the underlying biological mechanisms and signaling pathways involved in fibrosis and inflammation
  • Gain an understanding of the biological drivers specific to nonalcoholic steatohepatitis (NASH) and cardiac fibrosis
  • Have an opportunity to put their questions to the panel during the live broadcast.

This webinar will last for approximately 60 minutes.

Speaker bios

Scott L. Friedman, M.D.

Mount Sinai Hospital
New York, NY

Dr. Friedman is the Dean for Therapeutic Discovery and chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York City. He has performed pioneering research into the underlying causes of scarring or fibrosis associated with chronic liver disease, an affliction that affects millions worldwide. His work has spawned an entire field that is now realizing its translational and therapeutic potential, with new antifibrotic therapies for liver disease reaching clinical trials. He completed his medical degree at the Icahn School of Medicine at Mount Sinai in 1979, undertaking his residency at Beth Israel Hospital, Harvard Medical School, Boston, Massachusetts, followed by a gastroenterology fellowship at the University of California San Francisco before assuming a faculty position there. He joined Mount Sinai in 2001 as chief of the Division of Liver Diseases. Dr. Friedman has given invited honorary lectures throughout the world and has been a named lecturer or visiting professor at over 30 institutions worldwide. He has received numerous awards, including the International Hans Popper Prize from the Falk Foundation in Freiburg, Germany, and the American Association for the Study of Liver Diseases Distinguished Achievement Award. He was also honored with the Shanghai Magnolia Gold Award from the mayor of Shanghai (2013) and the China Friendship Award from the Premier of China (2014) in recognition of his efforts to improve the health of the residents of Shanghai and China through his research achievements.

Douglas E. Vaughan, M.D.

Northwestern University Feinberg School of Medicine
Chicago, IL

Dr. Vaughan is the Irving S. Cutter Professor and chair of the Department of Medicine at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. He received his M.D. from the University of Texas Southwestern Medical School in Dallas and completed his internship and residency in internal medicine at Parkland Memorial Hospital/Veterans Administration Medical Center, also in Dallas. He subsequently undertook a fellowship in cardiology at Brigham and Women’s Hospital and Harvard Medical School in Boston, Massachusetts. He is a fellow of the American College of Cardiology, and has been elected to membership in the American Society for Clinical Investigation and the Association of American Physicians. As a principal clinical investigator, Dr. Vaughan’s work ranges from the bench to the bedside. His efforts and findings in vascular biology include basic investigations into the regulation of gene expression, genetic models of disease, mechanistic studies in humans, and clinical trials. His primary research interests are in the mammalian plasminogen activator system and the role it plays in cardiovascular disease and physiological aging.

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here